Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) is trading higher on receiving positive efficacy data, with RECCE® 327 (R327) demonstrating significant antibacterial activity against E. coli urinary tract infections (UTI) by Murdoch Children’s Research Institute in a physiologically relevant rat UTI model.
R327 is undergoing a Phase I/II UTI/urosepsis rapid infusion clinical trial to address needs at first patient presentation in GP and hospital settings.
Moving forward, the results of the UTI study support the potential for the present phase I/II clinical trial.
The company's shares are 8.33% higher in ASX trading this morning to A$0.52 while the company's market cap is approximately A$105.92 million.
“Instils confidence”
Recce CEO James Graham said: “We are delighted to have received further UTI efficacy data from the two studies conducted at Murdoch Children's Research Institute.
“This instils confidence in the prospect of advancing R327 to a Phase II clinical trial for UTI/Urosepsis."
UTIs are most commonly caused by E. coli bacteria (Gr-) with 404.6 million individuals having UTIs globally in 2019= and ~80% resistant to two or more antibiotics.
In 2017, UTI-associated healthcare costs totalled more than A$7.56 billion annually.
If undiagnosed or untreated, UTIs can progress to systemic bacteraemia infections, which can trigger sepsis and septic shock.2
Forward plan
R327 is undergoing a Phase I/II UTI/Urosepsis rapid infusion clinical trial to deliver the drug at faster infusion rates as a broad-spectrum anti-infective across the full spectrum of UTIs (simple, complicated and recurring) through to their all-out septic state ‘Urosepsis’.
The fast I.V. infusions with ex vivo testing of participants' urine containing R327 to kill E. coli are progressing as planned.
The study further investigates R327 as a viable treatment option for first-patient presentation in both early-stage (GP) and late-stage (hospital) settings.